Alpha 2.0
Login Register
» Journals » J Immunother Cancer

Journal for Immunotherapy of Cancer

The Journal for Immunotherapy of Cancer is a peer-reviewed publication dedicated to advancing the field of cancer immunotherapy. It provides a platform for researchers, clinicians, and scientists to share their latest findings, clinical trials, and innovative approaches in harnessing the immune system to treat and prevent cancer. With a focus on immunotherapeutic strategies, this journal aims to accelerate the development of effective and personalized cancer treatments.
Details
Abbr. J Immunother Cancer
Start 2013
End Continuing
e-ISSN 2051-1426
Country United Kingdom
Language English
Specialties Oncology
Pharmacology
Allergy & Immunology
Metrics
h-index / Ranks: 2345 117
SJR / Ranks: 409 3728
CiteScore / Ranks: 508 16.80
JIF / Ranks: 401 10.9
Recent Articles
1.
Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancers
Drouin A, Durand L, Esnault C, Gaboriaud P, Leblond V, Karim S, et al.
J Immunother Cancer . 2025 Mar; 13(3). PMID: 40086820
The cell adhesion protein CD56 has been identified as a potential therapeutic target in several solid tumors and hematological malignancies. Recently, we developed a CD56-directed antibody-drug conjugate (ADC), called Adcitmer...
2.
Protein arginine methyltransferase 6 enhances immune checkpoint blockade efficacy via the STING pathway in MMR-proficient colorectal cancer
Duan J, Chen T, Li Q, Zhang Y, Lu T, Xue J, et al.
J Immunother Cancer . 2025 Mar; 13(3). PMID: 40086819
Background: The emergence of immunotherapy has revolutionized the paradigm of cancer treatment with immune checkpoint blockades (ICB) in solid cancers, including colorectal cancer (CRC). However, only a small subset of...
3.
Targeting MARCO in combination with anti-CTLA-4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming
Takahashi H, Perez-Villarroel P, Falahat R, Mule J
J Immunother Cancer . 2025 Mar; 13(3). PMID: 40081947
Background: Strategies to improve the therapeutic efficacy of cancer immunotherapy with immune checkpoint inhibitors include targeting additional immunosuppressive compartments in the tumor microenvironment (TME). Inhibitory macrophages (Mφ) can be one...
4.
Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager
Kosti P, Abram-Saliba J, Pericou-Troquier L, Pavelot S, Ruggeri T, Laffaille M, et al.
J Immunother Cancer . 2025 Mar; 13(3). PMID: 40081946
Background: The glycosylphosphatidylinositol-anchored cell surface protein mesothelin (MSLN) shows elevated expression in many malignancies and is an established clinical-stage target for antibody-directed therapeutic strategies. Of these, the harnessing of autologous...
5.
Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer
Kang Y, Kim H, Cho H, Park Y, Lee J, Ryu M
J Immunother Cancer . 2025 Mar; 13(3). PMID: 40081945
Background: Based on the phase 3 PRODIGY study, neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) have emerged as a viable treatment option for Asian patients with resectable locally advanced gastric cancer...
6.
promoter hypomethylation correlates with enhanced immune cell infiltration, favorable prognosis, and immunotherapy response in melanoma
Yang M, Zheng C, Miao Y, Yin C, Tang L, Zhang C, et al.
J Immunother Cancer . 2025 Mar; 13(3). PMID: 40081944
Background: Immune checkpoint blockade (ICB)-based immunotherapy has significantly improved survival in advanced melanoma. However, many patients exhibit resistance to these therapies. This study examines the impact of promoter methylation on...
7.
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells
Pilard C, Roncarati P, Ancion M, Luyckx M, Renard M, Reynders C, et al.
J Immunother Cancer . 2025 Mar; 13(3). PMID: 40081943
Background: Originally identified for its involvement in bone remodeling, accumulating data emerged in the past years indicating that receptor activator of nuclear factor κB ligand (RANKL) actually acts as a...
8.
Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer
Sun Y, Zhou L, Gu X, Zhao J, Bi J, Pan L
J Immunother Cancer . 2025 Mar; 13(3). PMID: 40081942
Background: Clinical trials have demonstrated the efficacy of bispecific antibodies in eliciting potent antitumor responses by redirecting T cells to target cancer cells, particularly for the treatment of hematologic malignancies....
9.
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer
Yeku O, Barve M, Tan W, Wang J, Patnaik A, LoRusso P, et al.
J Immunother Cancer . 2025 Mar; 13(3). PMID: 40081941
Background: Novel treatment options are required in patients with platinum-resistant ovarian cancer (PROC). Myeloid-derived suppressor cells promote a hostile tumor microenvironment and are associated with worse clinical outcomes in PROC....
10.
Novel anti-CD73-IL-2v bispecific fusion protein augments antitumor immunity by alleviating immunosuppressive adenosine pathways in CD8 T cells
Shin K, Park M, Kim S, Lee H, Lee Y, Kim J, et al.
J Immunother Cancer . 2025 Mar; 13(3). PMID: 40081940
Background: Adenosine accumulated in the tumor microenvironment functions as an immune-modulating factor, exerting immunosuppressive actions via adenosine A2A/A2B receptor (A2AR/A2BR) in various immune cell types. CD73, a key enzymatic regulator...